Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $96.38M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 1.66M
Average 2.44M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +31.8% | +9.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +31.8% over three years. Forward estimates point to Revenue at +9.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
OmniAb, Inc. NASDAQ:OABI | $716.17M | $4.91 | Not rated | -5.2 | +201.20% |
Prenetics Global Limited NASDAQ:PRE | $279.64M | $16.51 | Undervalued | -4.9 | -19.95% |
Profound Medical Corp. NASDAQ:PROF | $271.77M | $7.42 | Not rated | -6.3 | +12.07% |
OraSure Technologies, Inc. NASDAQ:OSUR | $249.95M | $3.62 | Not rated | -4.0 | +71.09% |
Codexis, Inc. NASDAQ:CDXS | $127.03M | $1.16 | Not rated | -7.1 | -33.12% |
Perspective Therapeutics, Inc. AMEX:CATX | $113.89M | $0.94 | Not rated | -0.0 | -63.02% |
Nyxoah S.A. NASDAQ:NYXH | $91.61M | $0.90 | Not rated | -0.7 | -81.13% |
Atlantic International Corp. NASDAQ:ATLN | $68.61M | $0.90 | Overvalued | -0.6 | -63.11% |
Sangamo Therapeutics, Inc. NASDAQ:SGMO | $30.66M | $0.07 | Not rated | -0.5 | -54.55% |
Continue the stock analysis
Jump to another research area for this company.